Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 27 | 3 | 30 |
| 1997 | 23 | 1 | 24 |
| 1998 | 21 | 8 | 29 |
| 1999 | 20 | 9 | 29 |
| 2000 | 21 | 9 | 30 |
| 2001 | 25 | 18 | 43 |
| 2002 | 22 | 11 | 33 |
| 2003 | 27 | 8 | 35 |
| 2004 | 25 | 15 | 40 |
| 2005 | 33 | 9 | 42 |
| 2006 | 27 | 13 | 40 |
| 2007 | 24 | 18 | 42 |
| 2008 | 37 | 7 | 44 |
| 2009 | 32 | 13 | 45 |
| 2010 | 37 | 9 | 46 |
| 2011 | 54 | 16 | 70 |
| 2012 | 41 | 18 | 59 |
| 2013 | 30 | 17 | 47 |
| 2014 | 50 | 14 | 64 |
| 2015 | 44 | 24 | 68 |
| 2016 | 49 | 17 | 66 |
| 2017 | 39 | 16 | 55 |
| 2018 | 51 | 19 | 70 |
| 2019 | 72 | 15 | 87 |
| 2020 | 48 | 21 | 69 |
| 2021 | 45 | 39 | 84 |
| 2022 | 12 | 50 | 62 |
| 2023 | 3 | 52 | 55 |
| 2024 | 41 | 38 | 79 |
| 2025 | 41 | 10 | 51 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
K-means clustering-based analysis of quantitative ultrafast DCE-MRI for predicting breast cancer response to neoadjuvant chemotherapy. J Appl Clin Med Phys. 2026 Jan; 27(1):e70439.
-
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Adv. 2025 Nov 11; 9(21):5665-5675.
-
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis. J Natl Cancer Inst. 2025 Nov 01; 117(11):2388-2393.
-
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology). Leukemia. 2025 Dec; 39(12):2926-2934.
-
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer. Ann Oncol. 2025 Nov; 36(11):1356-1365.
-
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025 Nov; 39(11):2697-2707.
-
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. J Clin Oncol. 2025 Oct 10; 43(29):3209-3220.
-
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia. Nat Rev Clin Oncol. 2025 Nov; 22(11):847-868.
-
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents. Leuk Lymphoma. 2025 Dec; 66(13):2437-2447.
-
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Future Oncol. 2025 Sep; 21(21):2823-2833.